Brazil Anvisa bans FarmaUSA tirzepatide batch over suspension non-compliance

Brazil's health regulator Anvisa issued a precautionary measure to seize and recall a batch of tirzepatide from FarmaUSA for failing to comply with a suspension term. The action targets a specific product batch, but details on the nature of the non-compliance and potential health risks remain unclear. This signals regulatory enforcement in the pharmaceutical sector, potentially affecting market access for the drug in Brazil.